- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Clarence Moore: Luspatercept Is a Positive Step Forward in Beta Thalassemia
Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses a new treatment option for beta thalassemia.
Transcript
What are the unmet needs for patients with beta thalassemia? What more needs to be done in terms of therapy options?
I think we are moving in the right direction. Luspatercept [Reblozyl] was FDA approved within the past year or so. So, I think we're moving right in the right direction. I know, historically, there hadn't been any real movement in the disease state itself. Having some form of medication to decrease blood transfusions in that patient population, I think, is huge. I think we're heading in the right direction. I know we'd always like to have more medications, but I think with the movements we're seeing right now, we're doing well.
In November 2019, the FDA approved Reblozyl as a treatment option for anemia in transfusion dependent patients. What are the benefits of having this additional therapy available?
So, having that additional therapy I think is great because to be able to actually decrease the amount of infusions that those patients potentially [need]. And that decreased amount required infusions changes the landscape of essentially what we've historically done in the beta thalassemia disease setting.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
